bioAffinity Technologies, Inc. SEC filings BIAFW
bioAffinity Technologies, Inc. has 399 filings in SEC EDGAR's recent list, going back to Jul 26, 2017. Its latest annual report, Form ARS, was filed on Mar 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 7, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Mar 16, 2026 | Dec 31, 2025 |
| 10-K | Annual report | Mar 16, 2026 | Dec 31, 2025 |
| ARS | Annual report to shareholders | Jun 2, 2025 | Dec 31, 2024 |
| 10-K/A | Amended annual report | Apr 29, 2025 | Dec 31, 2024 |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| ARS | Annual report to shareholders | Apr 15, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Apr 1, 2024 | Dec 31, 2023 |
| 10-K | Annual report | Mar 31, 2023 | Dec 31, 2022 |
Showing 8 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- BIAF (Nasdaq), BIAFW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Antonio, TX
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1712762
- Former names
- bioAffinity Technologies, Inc. (until Nov 3, 2026)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.